Sponsor

Fore Biotherapeutics Inc.

United States 3675 Market Street, 19104-2897, United States

About the sponsor

Fore Biotherapeutics Inc. focuses on clinical research in solid tumorsprimary central nervous system tumors with BRAF alterations, including BRAF fusions and BRAF V600E mutations.

Locally advanced solid tumors
Metastatic cancer
Rare solid tumors
Recurrent primary CNS tumors

The sponsor’s clinical activity is centered on targeted treatment strategies for cancers driven by specific BRAF pathway changes.

About Specializations

Fore Biotherapeutics Inc. runs clinical trials in conditions such as BRAF V600E mutation positive, BRAF gene mutation, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

1 clinical trial

BRAF V600E mutation positive+1

Recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cobicistat
Sponsor:Fore Biotherapeutics Inc.

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →